Clinical Trials Update
July 2008
BRAND NAME (OTHER NAMES)
COMPANY/SPONSOR
INDICATION
AranespTM (darbepoetin alfa, NESP)
Amgen
Anemia caused by kidney disease or some forms of chemotherapy.
FDA Ganite (gallium nitrate)
Genta Inc.
For treatment of cancer-related hypercalcemia.
REvlImID® (CC-5013, lenalidomide)
Celgene Corporation
For use with dexamethasone for the treatment of myeloma patients who have had at least one prior therapy.
vElCADE® (bortezomib, PS-341)
millennium Pharmaceuticals
In June 2008, vElCADE®'s approval was expanded to include previously untreated myeloma patients.
EvEREST - vElCADE®
millennium Pharmaceuticals
Assessing the efficacy, safety, and tolerability of retreatment with VELCADE®
AmD-3100 mozobil®
Genzyme
Stem Cell mobilizer used with G-CSF prior to transplant. Trial now closed to enrollment; accrual complete.
III Bondronat (ibandronate)
Hoffmann-la Roche
Randomized study of Bondronat versus Zometa for patients with malignant bone disease experiencing moderate to severe pain.
DOXIl®* (doxorubicin liposome HCl injection)
Ortho Biotech
Clinical trials using Doxil in place of Adriamycin in vAD; in combination with vElCADE® and dex; and in combination with vincristine, dex, and thalidomide.
DOXIl® /CAElYX and vElCADE or vElCADE monotherapy
Ortho Biotech
For patients whose disease has progressed after an initial response to at least 1 line of prior therapy or was refractory to initial treatment.
Genasense® (oblimersen, Bcl-2 antisense, G3139)
Genta, Inc. & Aventis
Combined with dexamethasone for treatment of relapsed myeloma.(Enrollment completed.)
REvlImID® (CC-5013, lenalidomide)
Celgene Corporation
A multicentre, randomised, double-blind, placebo-controlled, 3-arm parallel group studyto determine the efficacy and safety of REvlImID® in combination with melphalan and prednisone
versus placebo plus melphalan and prednisone in subjects with newly diagnosed multiple myeloma who are 65 years or older. (Note: This study is being conducted outside the US.)
tanespimycin (KOS-953, 17-AAG)
Kosan Biosciences
Open-label trial for MM patients in first relapse with tanespimycin plus bortezomib (Velcade) compared to bortezomib alone.
Thalomid®* (thalidomide)
Celgene Corporation and the NCI
Randomized study of thalidomide + prednisone as maintenance therapy after auto-transplant; randomized study of combination chemotherapy with or without thalidomide (Europe only)..
KOS-953 (tanespimycin, 17-AAG)
Kosan Bioscience
Tanespimycin in combination with bortezomib for patients who have been treated with and progressed following at least three prior therapies;
II/III
prior regimens must include lenalidomide and bortezomib.
mAGE-A3 and NY-ESO-1 (peptide vaccination)
University of Arkansa and Celgene Corp.
Subcutaneous peptide vaccination in combination with DT-PACE and autotransplant.
AmG162 (denosumab, osteoprotegerin, OPG)
Amgen
For treatment of patients with bone metastases due to advanced solid tumors or multiple myeloma and for the treatment of patients with relapsed or plateau-phase multiple myeloma.
II Aplidin®
Pharmamar, SA
For relapsed or refractory myeloma
AP23573
Ariad Pharmaceuticals
Rapamycin analog for refractory or recurrent malignancy, including myeloma and lymphoma.
Atiprimod
CalistoPharmaceuticals
For patients with refractory multiple myeloma who have failed two or more prior therapies.
ATN-224
Attenuon, llC
Given in combination with velcade to patients who are relapsed from or refractory to velcade.
AvastinTM (bevacizumab, rhumAb-vEGF)
Genentech Inc.
Given in combination with velcade to patients with relapsed/refractory mm.
azacitidine (vidaza® )
Investigator initiated
Drug previously approved in US for mDS being used in clinical trial for rel/ref mm in melbourne, Australia.
Bexxar (Iodine I 131 tositumomab)
GlaxoSmithKline, U of michigan
Radioactive antibody to CD20-expressing cells for patients with newly diagnosed or relapsed multiple myeloma.
Campath-1H (alemtuzumab, monoclonal antibody CD52)
NCI and Fred Hutchinson Cancer Research Institute
Used before allo transplant to prevent GvHD
carfilzomib (PR-171)
Proteolix
Study of carfilzomib in relapsed and refractory mm at St. Vincent' s Hospital in NY.
CC4047 (formerly "Actimid") (pomalidomide)
mayo Clinic
For patients with relapsed disease who have had three or fewer previous regimens.
Celebrex (celecoxib)
National Cancer Institute
Prevention study for patients with mGUS or smoldering myeloma.
CG53135-05
CuraGen
For treatment of oral mucositis in patients undergoing autologous stem cell transplant
CNTO 328
Centocor
Given in combination with vElCADE® to patients with relapsed/refractory mm.
CTY997
Cytopia limited
Prospective, single-arm, open-label trial of a vascular-disrupting agent in the treatment of relapsed/refractory mm.
dasatinib (SprycelTM; BmS-354825)
Bristol-myers Squibb
BCR/ABl and Src tyrosine kinase inhibitor for treatment of relapsed or plateau phase mm.
Dendritic Cell vaccine
Arkansas Cancer Research Center
Autologous dendritic cells for high-risk mutiple myeloma.
DlI (donor lymphocyte infusion)
National Cancer Institute
For relapse following allo transplant.
eltrombopag (SB-497115; "115")
GlaxoSmithKline
Small-molecule drug that mimics the activity of thrombopoietin (TPO) to promote growth and production of platelets.
Erbitux, cetuximab
Imclone
monoclonal antibody targeted to the EGFR. Trial is open to all stages of myeloma; patient must have had at least one prior treatment with disease progression.
Ethyol® (amifostine)
medImmune, Inc.
Cytoprotective agent to allow higher-dose melphalan in high-dose therapy with auto-transplant.
FR901228 (depsipeptide)
National Cancer Institute
Novel chemotherapy agent for relapsed/refractory myeloma.
Gallium maltolate
Titan Pharmaceuticals
Treatment of myeloma-related bone disease.
Genasense (oblimersen, Bcl-2 antisense, G3139)
Genta, Inc.
Trials combining Genasense with other regimens in relapse setting.
Gm-CSF (leukine)
US Oncology
maintenance therapy post auto transplant for mm
GvAX
Cell Genesys, Inc.
Newly diagnosed myeloma patients undergoing transplant.
INCB018424 (JAK2-inhibitor)
Incyte Corporation
Small molecule Janus kinase inhibitor for patients with rel/ref mm.
ITF2357
Italfarmaco
Histone deacetylase inhibitor given as monotherapy to patients with relapsed or progressive mm.
KineretTM (anakinra)
Amgen
mayo (Rochester) study of Il-1beta antagonist for smoldering/indolent mm
KIR-ligand mismatched Haplo-Identical Natural Killer Cells
Arkansas Cancer Research Center
For relapse after single or tandem transplant and for high-risk multiple meloma.
KlH vaccine (keyhole limpet hemocyanin)
National Cancer Institute
low or intermediate risk myeloma patients undergoing autotransplant.
lBH589
Novartis
HDAC inhibitor for patients with relapsed/refractory myeloma who have received at least two prior lines of therapy and whose disease has progressed on the latest therapy.
mapatumumab (HGS-ETR1; TRm-1; HGS1012)
Human Genome Sciences
monoclonal antibody to TRAIl-R1 used in combination with bortezomib in patients with relapsed or refractory myeloma.
Neotrofin® (leteprinim potassium)
NeoTherapeutics
For treatment of chemotherapy-induced peripheral neuropathy. (Enrollment completed.)
Neulasta® (pegfilgrastim, pegylated G-CSF)
Amgen
Pegylated G-CSF (filgrastim) for stem cell mobilization prior to harvest.
Nexavar® (BAY 43-9006, sorafenib, sorafenib tosylate)
Bayer and Onyx Pharmaceuticals
Oral therapy targeted to receptor tyronsine kinases involved with both tumor cell proliferation and angiogenesis; for patients with relapsed or refractory myeloma.
O-6-benzyl-guanine
National Cancer Institute and Pacific Pharmaceuticals
Novel chemotherapy for treatment of relapsed myeloma.
PanzemTM (2-meth-oxyestradiol, 2mE2)
Entremed, Inc.
Antiangiogenesis agent for treatment of relapsing myeloma.
PD 0332991
Pfizer
In combination with velcade and dexamethasone in patients who have received at least one prior treatment for mm.
perifosine (KRX-0401)
Keryx Pharmaceuticals, Inc.
Akt pathway inhibitor known as an alkylphosphocholine. Ph II safety and efficacy trial with perifosine alone and in combination with dexamethasone.
PI-88
Progen Industries limited
Phase II trial of vEGF inhibitor completed in Australia; early planning stages in US.
Prochymal
Osiris Therapeutics
For treatment of GvHD (graft versus host disease) following allo transplant.
Proleukin® (Il-2, Interleukin-2)
National Cancer Institute and Chiron
For advanced myeloma as part of auto or syngeneic transplant.
PTK787
Novartis and Schering, AG
Novel oral angiogenesis inhibitor as post-transplant maintenance following high-dose therapy and autologous SCT.
PXD101
CuraGen and TopoTarget A/S
Small molecule histone deacetylase inhibitor for mm patients who have failed at least two prior treatment regimens.
Quadramet® (EDTmP, samarium-153 ethylene diamine
mayo Clinic, Rochester, mN
In combination with standard high-dose chemotherapy for patients undergoing stem cell transplant.
tetramethylene phosphonate Samarium)
RAD001 (everolimus)
Novartis
mTOR (mammalian target of Rapamycin) inhibitor for patients with relapsed/refractory mm
REvlImID® (CC-5013, lenalidomide)
Celgene
In combination with Biaxin and dexamethasone for newly-diagnosed myeloma.
Rituxan (rituximab)
NCI
High-dose cyclophosphamide in combination with rituximab in patients with primary refractory, high-risk, or relapsed myeloma; also being studied for the treatment of peripheral
neuropathy in patients with mGUS.
SCIO-469
Scios, Inc.
Relapsed, refractory mm
sorafenib
See Phase II Nexavar.
sunitinib (sunitinib malate, Sutent®)
NCI
Multicenter efficacy trial of oral agent previously approved for GIST and kidney cancer.
Temodar® (temozolomide)
Schering-Plough Corp.
Combined with prednisone for relapsed or refractory myeloma. Study closed to enrollment.
THAlOmID®* (thalidomide)
Celgene Corporation
Used with dexamethasone as induction therapy before, and with prednisone as maintenance therapy after high-dose therapy with stem cell transplant.
vEGF Trap (NSC 724770)
Regeneron
Open-label safety and efficacy study for patients with relapsed or refractory multiple myeloma.
vElCADE® (bortezomib, PS-341, lDP-341, mlN-341)
millennium Pharmaceuticals, Inc.
Trials for frontline and maintenance therapy..
Xcytrin (motexafin gadolinium)
Pharmacyclics
Relapsed and refractory myeloma.
Xl999
Exelixis, Inc.
Potent small molecule inhiitor of recepto tyrosine kinases FGF, vEGF, and PDGF being evaluated in patients with relapsed or refractory mm.
ZIO-101
ZIOPHARm, Inc.
multi-center trial of small-molecule organic arsenic.
ActimidTM (CC-4047)
Celgene Corporation
Immunomodulatory agent for relapsed/refractory myeloma. Trials only in UK.
I/II Amplimexon (imexon)
Amplimed Corp.
Rapamycin analog administered Iv.
AvE1642
Sanofi-Aventis
Anti-IGF-1R monoclonal Antibody combined with bortezomib for patients with rel/ref mm
AvN944
Avalon Pharmaceuticals
Open-label, repeat-dose escalation, safety and tolerability trial for patients with advanced hematological malignancies.
BrevaRex®
AltaRex
Trials planned for monoclonal antibody against mUC1 antigen.
Brostallicin (PNU-166196)
Pharmacia and NCI
For the treatment of recurrent or refractory multiple myeloma.
CB3304 (noscapine)
Cougar Biotechnology
Oral alkaloid derived from opium; trial for relapsed/refractory mm. Site: NY Presbyterian Cornell/Weill med. Center, PI Ruben Niesvizky.
CERA (Continuous Erythropoiesis Receptor Activator)
Roche
Treatment of cancer-related anemia
CNTO 328
Centocor
monoclonal antibody to Il-6
Curcumin (diferuloyl-methane)
mD Anderson CC
Present in turmeric and yellow mustard, inhibits NF-kappaB.
Defibrotide
Gentium S.p.A.
Used as a mm cell sensitizer in combination with melphalan, prednisone, thalidomide as salvage treatment in advanced myeloma.
GCS-100lE
GlycoGenesys, Inc.
Dose-escalation study of polysaccharide-based (carbohydrate) agent for relapsed/refractory myeloma.
hll1 (anti-CD74 mAb; ImmU 115)
Immunomedics
Open-label, multi-center study of a humanized monoclonal antibody to the CD74 myeloma cell surface antigen for patients with recurrent or refractory multiple myeloma who have failed at
least two prior standard systemic treatments
Humax-CD38 (human IgG1, k antibody)
Genmab A/S
Antibody to the CD 38 molecule, which is highly expressed on the surface of mm cells.
hydroxychloroquine (plaquenil)
NCI
FDA-approved anti-inflammatory drug for malaria, lupus, and rheumatoid arthritis in trials with Velcade for rel/ref mm. (For WNiCT, you should add that site is Abramson Cancer Center at the
University of Pennsylvania, Edward Stadtmauer PI, contact tel 215-662-7910.)
Idiotypic vaccination + mini-allo transplant
University Clinic of Navarre, Pamplona, Spain
Patients (either newly-diagnosed or in partial response following autologous transplantation) with HlA full-matched, sibling donor.
milatuzumab (humanized anti-DC74 monoclonal antibody)
Immunomedics, Inc.
To determine safety and efficacy of the naked antibody for the treatment of myeloma before conjugating the antibody with a drug or toxin (see IMMU-110 in preclinical)
P276-00
Nicholas Piramal India ltd (NPIl)
Study to determine safety and efficacy of intravenous Cdk4-D1 and Cdk1-B inhibitor. Study sites limited to Canada
Quadramet (samarium Sm-153 lexidronam)
Cytogen Corporation
For the treatment of bone pain associated with metastatic bone disease in patients with recurrent or refractory myeloma.
simvastatin (Zocor®)
Investigator
Danish trial to assess effect of high-dose simvastatin on bone metabolism and markers of disease in mm.
Stemgen
Amgen
Tested abroad as stem cell booster; protocols pending in US.
TacI-Ig
ZymoGenetics
Fusion protein given to patients with relapsed/refractory myeloma
temsirolimus (ToriselTM, CCI-779)
Wyeth
m-TOR inhibitor in combination with bortezomib (velcade) for rel/ref mm.
TrisenoxTM (arsenic trioxide injection)
Cephalon Oncology
With vitamin C for relapsed and refractory multiple myeloma.
vElCADE® (bortezomib,PS-341, lDP-341, mlN-341)
millennium Pharmaceuticals
With Adriamycin and dex as front-line therapy. (UK only)
vElCADE® (bortezomib,PS-341, lDP-341, mlN-341)
millennium Pharmaceuticals
As maintenance therapy after auto-transplant in patients with intermediate or advanced mm.
vQD-001 (sodium stibogluconate, SSG)
vioQuest Pharmaceuticals, Inc.
Targeted to protein tyrosine phosphatases; safety, efficacy, and tolerability trial for solid tumors, lymphoma, and myeloma.
1D09C3
GPC Biotech
Anti-major histocompatibility complex (mHC) class II monclonal antibody that has received orphan medicinal product designation for the treatment of myeloma by the
I
European medicines Agency.
Allomune System
BioTransplant
To facilitate acceptance of donor stem cells.
anti-IGF-1R mAb (CP-571,871); monoclonal antibody to
Pfizer
Relapsed and refractory mm.
insulin-like growth factor-1 receptor)
anti-KIR mAb (1-7F9)
Novo Nordisk
Safety and tolerability study for patients with relapsed/refractory mm
AP24534
Ariad Pharmaceuticals
maximum tolerated dose of AP24534 in Cml and other hematologic malignancies.
ARRY-614
Array BioPharma
Orally active p38/Tie2 inhibitor in dose escalation trial.
AvE1642
Sanofi-Aventis
Anti-IGF-1R monoclonal Antibody combined with bortezomib for patients with rel/ref mm.Sites: University Hospital, Nantes, France; University Hospital, lille, France;
University Hospital, Torino, Italy
BB-10901 (huN901-Dm1, huN901-N2'-Deacetyl-N2-
ImmunoGen , Inc.
Targets and kills cancer cells that express the CD 56 antigen. A humanized monoclonal antibody coupled with a cancer-killing agent.
(3-mercapto-1-oxopropyl)-maytasine)
Campath-1H (alemtuzumab, monoclonalantibody CD52)
National Cancer Institute and Fred Hutchinson
Used before mismatched allo transplant to prevent GvHD.
Cancer Research Institute
CC 3304, noscapine
Cougar Biotech
Dose escalation and safety study for patients with relapsed/refractory multiple myeloma
dendritic cell vaccine
Rockefeller University Hospital
Autologous dendritic cells pulsed with alpha-galactosyl ceramide for patients with perisistent or relapsed mm after initial therapy
ENmD 0995 (analog S-3APG)
Entremed
Thalidomide analog.
enzastaurin (lY317615.HCl)
Eli lilly
Safety study in combination with bortezomib in rel/ref mm.
fenretinide (4-HPR)
California Cancer Consortium; NCI
Intravenous chemotherapy agent in a safety and tolerability study for patients with relapsed or refractory hematologic cancer
Flavopiridol (HmR 1275, l86-8275)
NCI; Aventis Oncology
Study of bortezomib and flavopiridol in patients with recurrent/refractory B-cell neoplasms to determine maximum tolerated dose, safety, and efficacy.
fluphenazine
Immune Control Inc.
Serotonin antagonist for relapsed/refractory mm.
GSK690693
GlaxoSmithkline
Maximum tolerated dose and efficacy study in hematologic malignancies.
HCD122 (CHIR-12.12)
Novartis andXoma ltd.
monoclonal antibody to CD40
Huluc63
PDl Biopharma, Inc & Dana-Farber
Novel humanized monoclonal antibody to CS1, a myeloma antigen expressed in more than 96% of mm patients.
IPI-504
Infinity Pharmaceuticals
Safety and efficacy trial of Heat Shock Protein 90 inhibitor on patients with relapsed/refractory mm.
KOS-953 (tanespimycin);
Kosan Biosciences
Inhibitor of heat shock protein 90 being evaluated both as monotherapy and in combination with vElCADE® for patients with relapsed, refractory multiple myeloma.
17-allylamino-17-demethoxy-geldanamycin)
lymphoRad® 131 (Radio-labeled BlyS Protein)
Human Genome Sciences
Iodine-labeled B lymphocyte stimulator.
measles virus (Oncolytic measles virus)
mayo Clinic
Engineering the virus to make it more user-friendly as an agent for cancer therapy
mRA (humanized anti-human Il-6 receptor mAb)
Chugai Pharma USA
Safety and efficacy study of monoclonal antibody to IL-6 in patients with myeloma.
mS-275
Berlex labs
For poor-risk hematologic malignancy.
myelovax
Apalexo Biotechnologie GmbH
For treatment of multiple myeloma.
NPI-0052 (salinos-poramide)
Nereus Pharmaceuticals
A single-agent, dose escalation study for patients with relapsed or relapsed/refractory multiple myeloma. Sites: Dana- Farber Cancer Institute,Ohio State University,
Roswell Park Cancer Institute and University of Chicago.
Palifermin
Amgen, Inc.
Supportive care to help prevent mucositis after HDT.
Product R
Advanced viral Research Corp.
For treatment of cachexia in patients with hematopoietic cancers, including mm.
Pyroxamide
National Cancer Institute
Histone deacytelase (HDAC) inhibitor for advanced malignancies.
REvlImID® (CC-5013, lenalidomide)
Celgene Corporation
Combined with Doxil, vincristine, and dexamethasone (Dvd) in relapsed/refractory mm.
REvlImID® (CC-5013, lenalidomide)
Celgene Corporation
Single-center study of Revlimid in combination with velcade for relapsed/refractory mm.
RHAmm-R3 peptide (IlSlElmKl)
University of Ulm, Germany, et al.
vaccine study with a CD8+ T cell epitope peptide derived from RHAmm for patients with Aml, mDS, and mm.
RTA 402 (CDDO-me)
Reata Pharmaceuticals, Inc.
Oral NF-kappa B inhibitor being tested for safety and efficacy in patients with solid tumors, lymphoma, and myeloma.
SAHA (suberoylanilide hydroxamic acid, SW 064652)
merck
Histone deacytelase (HDAC) inhibitor for advanced myeloma
SGN-35
Seattle Genetics
Safety profile and pharmacokinetic parameters of SGN-35 in patients with rel/ref CD30-positive hematologic malignancies.
SGN-40 (Phase IB)
Seattle Genetics
Open-label, single-arm study of SGN-40 in escalating doses in combination with Revlimid and dexamethasone for patients with rel/ref mm.
SNS-032
Sunesis
Dose-excalation study to examine the safety and tolerability, as well as preliminary anti-tumor activity, of a novel targeted inhibitor of CDKs 2, 7 and 9, in patients with B-cell malignancies.
temsirolimus (CCI-779, ToriselTM)
Wyeth
m-TOR inhibitor in combination with lenalidomide (Revlimid) for rel/ref mm.
Th2 Cells
National Cancer Institute
For prevention of GvHD following mini allogeneic transplant.
THAlOmID®* (thalidomide)
Arkansas Cancer Research Center
Used in combination with vElCADE® for refractory multiple myeloma.
Thymoglobulin
SangStat medical Corp.
Drug approved for treatment of kidney transplant rejection now in study for patients with rel/ref mm. For more information about this trial, please contact Nick Fisher, manager of Oncology
(rabbit-derived polyclonal anti-thymocyte globulin)
Clinical Research at Wash U, at 314-454-5102.
TKI-258
Novartis
A novel, multitargeted tyrosine kinase inhibitor for the treatment of relapsed/refractory multiple myeloma.
TPA (12-O-tetradeca-noylphorbol-13-acetate)
Cancer Institute of New Jersey and NCI
Chemotherapy agent for treatment of relapsed/refractory hematologic malignancies.
Triapine®
vion
DNA synthesis inhibitor combined with cytarabine in hematologic malignancies.
(3-Aminopyridine-2-carboxaldehyde Thiosemi-carbazone)
TrisenoxTM (arsenic trioxide injection)
Cephalon Oncology
Apoptosis inducer for relapse.
vElCADE® (bortezomib, PS-341, lDP-341, mlN-341)
millennium Pharmaceuticals, Inc.
Trials combining vElCADE® with other agents in relapse setting..
vNP40101m
vion
Novel alkylating agent in combination with cytarabine for patients with hematologic malignancies.
vQD-001, SSG, stibogluconate
vioQuest Pharmaceuticals, Inc.
Targets protein tyrosine phosphatases. Trial is open at the Cleveland Clinic Cancer Center to examine the effectiveness, safety, and tolerability of SSG for the treatment of solid tumors,
lymphoma, and myeloma.
Zarnestra (tipifarnib, FTI R115777, R115777)
Johnson & Johnson
multi-center trial to determine optimal dosing of vElCADE® (bortezomib) in combination with Zarnestra (tipifarnib) for the treatment of relapsed/refractory mm.
Zolinza (vorinostat, SAHA)
merck
HDAC inhibitor that has already been approved for cutaneous T-Cell lymphoma and is now being studied in myeloma in combination with bortezomib (vElCADE®).
Phase I Assess side effects of the treatment and determine a maximum tolerated dose.
* Approved for prescription by the US Food and Drug Administration prior to January 2001, but are not specifically indicated for the treatment of multiple myeloma.
Phase II Assess anti-myeloma effects of treatment at the dose established in Phase I trial.
Phase III Compare a newer treatment against current standard treatment.
FDA FDA approved, but further testing desired post-approval
To view a complete listing of drugs in Clinical Trials for myeloma, please visit the IMF website at www.myeloma.org.
©2008 IMF International Myeloma Foundation The Myeloma Matrix is supported by unrestricted educational grants from Celgene Corporation and Millennium Pharmaceuticals.
2002
Daniel Sze
martha lacy
Hervé Avet-loiseau
Royal Prince Alfred Hospital
mayo Clinic
(continuing support)
Sydney, Australia
Rochester, minnesota
Institute de Biologie
Nantes, France
Amir Toor
Babatunde O. Oyajobi
University of Arkansas
University of Texas Health
little Rock, Arkansas
Science Center
2008
2006
2004
Elliot Epner
(continuing support)
San Antonio, Texas
William matsui, m.D.
Tuna mutis
manuel Penichet
University of Arizona
2000
Sidney Kimmel
University of Utrecht
University of California,
Ray Alexanian USA
Robert Kyle USA
Tucson, Arizona
Gregory R. mundy
Roger N. Pearse
Comprehensive Cancer
Utrecht, Netherlands
los Angeles
Kenneth Anderson USA
Jae Hoon lee South Korea
University of Texas
memorial Sloan-Kettering
Center at Johns Hopkins
los Angeles, California
michel Attal France
Henk lokhorst
michael A. morgan
Health Science Center
Cancer Center
Baltimore, mD
David Agus
Hervé Avet-loiseau France
The Netherlands
Hannover medical School
San Antonio, Texas
New York, New York
Proteomics Team
marco ladetto
Ashraf Badros USA
Sagar lonial USA
Hannover, Germany
Silvia ling, m.D.
Joan Bladé Spain
Heinz ludwig Austria
Cedars Sinai Comprehensive
University of Turin
Håkan mellstedt
Ivan van Riet
Bart Barlogie USA
Juan lahuerta Spain
Centenary Institute
Cancer Center
Turin, Italy
Jamie Claudio
Karolinska Institute
Free University Brussels
Regis Batail e France
Angelo maiolino Brazil
of Cancer medicine
los Angeles, California
Toronto General
Stockholm, Sweden
Brussels, Belgium
meral Beksac Turkey
Jayesh mehta USA
and Cell Biology
Chao-lan Yu
Research Institute
Andrew Belch Canada
Giampaolo merlini Italy
Newton, NSW Australia
Alexei Kisselev
vanderbilt University
Toronto, Canada
Elliot Epner
Kim Orchard
Dina Ben Yehuda Israel
Philippe moreau France
Norris Cotton Cancer Center
School of medicine
University of Arizona
Royal Free Hospital
Bil Bensinger USA
Gareth morgan U.K.
Sonia vallet, m.D.
Dartmouth College
Nashville, Tennesee
Amit Nathwani
Tucson, Arizona
london, England
mario Boccadoro Italy
Yana Novis Brazil
massachusetts
Hanover, New Hampshire
University College london
michele Cavo Italy
Antonio Palumbo Italy
General Hospital
mathias Oelke
medical School
Roger N. Pearse
Catherine Pellat-Deceunynck
Wen-ming Chen China
Santiago Pavlovsky
Boston, mA
Brian O'Nuallain
Johns Hopkins University
(2nd year renewal)
Central laboratory
Tony Child U.K.
Argentina
University of Tennessee
london, England
medical School
Rockefeller University
of Hematology
James Chim Hong Kong
Ruben Niesvizky USA
Karin vanderkerken, Ph.D.
medical Center
Baltimore, maryland
Ray Comenzo USA
Amara Nouel venezuela
Atanasio Pandiella
New York, New York
University Hospital
vrije Universiteit Brussel
Knoxville, Tennessee
John Crowley USA
Raymond Powles U.K.
Centro de Investigación
Nantes, France
(vUB)
Francesco Piazza
Wil iam Dalton USA
linda Pilarski Canada
del Cancer
Rudi Hrncic
Brussels, Belgium
Giovanni Tonon
venetian Institute
Faith Davies U.K.
vincent Rajkumar USA
Dana Farber Cancer Institute
University of Salamanca
University of Tennessee
1998
of molecular medicine
michel Delforge Belgium
Donna Reece Canada
Salamanca, Spain
medical Center
Anna masellis
Jing Yang, Ph.D.
Harvard medical School
University of Padova
meletios A. Dimopoulos Greece
Tony Reiman Canada
Knoxville, Tennessee
virginia Piper
Angela Dispenzieri USA
Paul Richardson USA
mD Anderson Cancer Center
Boston, massachusetts
Padova, Italy
Klaus Podar
Cancer Institute
Hermann Einsele Germany
Angelina Rodríguez morales
Houston, Texas
Nicolà Giuliani
Hideaki Ishikawa
Dana-Farber Cancer Institute
Anders Sundan
Abbott Northwestern
Thierry Facon France
venezuela
Boston, massachusetts
Institute for Cancer Research
Hospital
Dorotea Fantl Argentina
Jesús San miguel Spain
Yutaka Okuno, m.D.
University of Parma
(IMF Japan Aki Award)
and molecular Biology
minneapolis, minnesota
Jean-Paul Fermand France
Orhan Sezer Germany
(IMF Japan Aki Award)
Parma, Italy
Yamaguchi University
Ivan van Riet
Norwegian University
Rafael Fonseca USA
John Shaughnessy USA
Kumamoto University
Yamaguchi City, Japan
Free University Brussels
of Science and Technology
matthew Rettig
Gösta Gahrton Sweden
Kazayuki Shimizu Japan
Kumamoto, Japan
Eishi Ashihara
morie Gertz USA
Chaim Shustik Canada
(IMF Japan Aki Award)
2003
Brussels, Belgium
Trondheim, Norway
University of California,
los Angeles
John Gibson Australia
David Siegel USA
2007
Kyoto University
Chao-lan Yu
masahiro Abe
Ivan van Riet
los Angeles, California
Hartmut Goldschmidt Germany
Seema Singhal USA
William matsui, m.D.
Kyoto, Japan
vanderbilt University
Philip Greipp USA
Pieter Sonneveld
(IMF Japan Aki Award)
Free University Brussels
School of medicine Oncology
School of medicine
Roman Hajek Czech Republic
The Netherlands
University of Tokushima
Brussels, Belgium
Steven P. Treon
Johns Hopkins University
2005
Nashville, Tennessee
Izhar Hardan Israel
Cármino de Souza Brazil
School of medicine
Dana-Farber Cancer Institute
Baltimore, maryland USA
Daniel Sze
Jean-luc Harousseau France
Andrew Spencer Australia
Royal Prince Alfred Hospital
Kewal Asosingh
Tokushima, Japan
Catherine Pellat-Deceunynck Harvard medical School
Hiroyuki Hata Japan
Keith Stewart USA
Central laboratory
Boston massachusetts
Yutaka Hattori Japan
Patrizia Tosi Italy
Roberto Bellucci, Ph.D.
Sydney, Australia
Free University Brussels
2001
for Haematology
Joy Ho Australia
Guido Tricot USA
Dana Farber Cancer Institute
Brussels, Belgium
Hervé Avet-loiseau
University Hospital
1997
vania Hungria Brazil
Ingemar Turesson Sweden
medical Oncology
H.m. lokhorst
Institut de Biologie
Nantes, France
leif Bergsagel
mohamad Hussein USA
Brian van Ness USA
Boston, massachusetts USA
University medical
lee-Ann Garrett-Sinah
Center Utrecht
State University
Nantes, France
Weill medical College
Shinsuke Iida Japan
Ivan van Riet Belgium
Peter Croucher
Cornell University
Peter Jacobs South Africa
Robert vescio USA
Claire Edwards, Ph.D.
Utrecht, The Netherlands
New York Buffalo
Robert G. Fenton
University of Sheffield
New York, NY
Sundar Jagannath USA
David vesole USA
vanderbilt University
Buffalo, New York
University of maryland
medical School
Hou Jian China
michael Wang USA
medical Center
Kewal Asosingh
Baltimore, maryland
Sheffield, England
Rena Feinman
Douglas Joshua Australia
Donna Weber USA
Nashville, Tennessee USA
Free University Brussel
Sun J. Choi
michio Kawano Japan
Jan Westin Sweden
Brussels, Belgium
University of Pittsburgh
Arkansas Cancer
Shaji Kumar USA
Jeffrey Zonder USA
Nancy Borson
Scott Schuetze
Research Center
Silvia ling, m.D.
Pittsburgh, Pennsylvania
mayo Clinic
Fred Hutchinson Cancer
University of Arkansas
Centenary Institute
Niels W.C. van de Donk
IMWG Ongoing Accomplishments
Rochester, minnesota
Research Center
for medical Sciences
of Cancer medicine
University medical
Takashi Sonoki
Seattle, Washington
little Rock, Arkansas
2003 Myeloma Management Guidelines
and Cell Biology
Center Utrecht
(IMF Japan Aki Award)
Elliot Epner
Newton, NSW Australia
Utrecht, The Netherlands
Kumamoto University
2003 Classification Criteria for Myeloma,
Kumamoto City, Japan
University of Arizona
Hon Jin mark ma
1996
MGUS, and related disorders
Tucson, Arizona
Brentwood Basic
melissa Alsina
Nicola Camp, Ph.D.
loren Erickson
Research Institute
University of Tennesee
2005 International Staging System
University of Utah
Dartmouth medical School
Rudi Hrncic
los Angeles, California
Knoxville, Tennesee
Biomedical Informatics
Hanover, New Hampshire
2006 International Uniform Response Criteria
University of Tennessee
Salt lake City, Utah USA
Yutaka Hattori
Knoxville, Tennessee
1999
1995
2007 Bisphosphonate Guidelines & Letter to the Editor
Rudi Hrncic
Akira Sakai
(IMF Japan Aki Award)
Atsushi Ogata
2007 DVT Guidelines
Klaus Podar
University of Tennessee
(IMF Japan Aki Award)
Keio Gijuku University
Dana Farber Cancer Institute
Dana Farber Cancer Institute
medical Center
2008 International Staging System Confirmation
Hiroshima University
Tokyo, Japan
Harvard medical School
Boston, massachusetts
Knoxville, Tennessee
Hiroshima, Japan
Boston, massachusetts
2008 Favorable outcomes in patients younger than 50
Chairman Robert A. Kyle, USA
Scientific Advisors Emeriti
Y.C. Chen, Republic of China
Ian Franklin, Scotland
Tadamitsu Kishimoto, Japan
Ian Maclennan, England
James S. Malpas, England
Scientific Advisors
Raymond Alexanian, USA
Kenneth C. Anderson, USA
Michel Attal, France
Michio M. Kawano, Japan
Hervé Avet-Loiseau, France
Henk M. Lokhorst,
Dalsu Baris, USA
The Netherlands
Bart Barlogie, USA
Sagar Lonial, USA
Régis Bataille, France
Heinz Ludwig, Austria
Meral Beksac, Turkey
Jayesh Mehta, USA
William Bensinger, USA
Håkan Mellstedt, Sweden
James R. Berenson, USA
Giampaolo Merlini, Italy
Leif Bergsagel, USA
Gareth Morgan, England
Joan Bladé, Spain
Gregory R. Mundy, USA
Mario Boccadoro, Italy
Nikhil Munshi, USA
J. Anthony Child, England
Amara Nouel, Venezuela
Raymond L. Comenzo, USA
Martin M. Oken, USA
John Crowley, USA
Antonio Palumbo, Italy
Franco Dammacco, Italy
Linda Pilarski, Canada
Faith Davies, England
Raymond Powles, England
Meletios A. Dimopoulos, Greece
S. Vincent Rajkumar, USA
Johannes Drach, Austria
Donna Reece, Canada
Brian G.M. Durie, USA
Paul Richardson, USA
Hermann Einsele, Germany
Angelina Rodríguez Morales,
Venezuela
Dorotea Fantl, Argentina
David Roodman, USA
Rafael Fonseca, USA
Jesús San Miguel, Spain
Gösta Gahrton, Sweden
Orhan Sezer, Germany
Morie A. Gertz, USA
Kazayuki Shimizu, Japan
John Gibson, Australia
Chaim Shustik, Canada
Hartmut Goldschmidt, Germany
David Siegel, USA
Roman Hajek, Czech Republic
Seema Singhal, USA
Jean-Luc Harousseau, France
Alan Solomon, USA
Joyce Ho, Australia
Pieter Sonneveld,
Vania Hungria, Brazil
The Netherlands
Mohamad Hussein, USA
Andrew Spencer, Australia
Sundar Jagannath, USA
A. Keith Stewart, USA
Douglas Joshua, Australia
Guido J. Tricot, USA
Benjamin Van Camp, Belgium
Brian Van Ness, USA
David Vesole, USA
Jan Westin, Sweden